TransMedics Group (NASDAQ:TMDX) Rating Increased to Buy at Wall Street Zen

Key Points

• TransMedics Group has been upgraded from a "hold" to a "buy" rating by Wall Street Zen, indicating positive sentiment towards the stock.
• The company's latest earnings report showed a significant 37.7% increase in revenue with earnings per share of $0.92, surpassing analysts' expectations.
• TransMedics Group's stock has seen a 1.7% increase recently, and currently holds a market capitalization of $4.01 billion.

TransMedics Group (NASDAQ:TMDX - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

TMDX has been the subject of several other reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $142.00 target price on shares of TransMedics Group in a report on Tuesday. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Monday, August 25th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a "hold" rating and a $115.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $127.18.

TransMedics Group Stock Up 1.7%

NASDAQ:TMDX opened at $117.63 on Friday. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The stock has a market capitalization of $4.01 billion, a P/E ratio of 60.95 and a beta of 2.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The company's 50-day simple moving average is $116.52 and its 200-day simple moving average is $113.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same period last year, the business earned $0.35 EPS. The company's revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.

Institutional Trading of TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after buying an additional 2,209,996 shares during the period. Geode Capital Management LLC raised its holdings in TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company's stock valued at $107,845,000 after buying an additional 11,241 shares during the period. Driehaus Capital Management LLC raised its holdings in TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company's stock valued at $52,395,000 after buying an additional 17,913 shares during the period. Marshall Wace LLP increased its stake in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after purchasing an additional 86,721 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.